FDA Refers Reckitt To FTC For Hindering Generic Suboxone

Law360, New York (February 25, 2013, 3:12 PM EST) -- The U.S. Food and Drug Administration on Friday approved the production of two generic versions of Reckitt Benckiser Pharmaceuticals Inc.’s opioid dependence treatment Suboxone, rebuking the company for hindering generic competition and requesting a Federal Trade Commission probe into its practices.

The FDA, in a letter responding to a citizen petition from Reckitt, accused the drugmaker of acting disingenuously in September when it said it would eventually discontinue sales of Suboxone tablets and instead sell only a dissolving film version it claims is less prone to...
To view the full article, register now.